Business
PDMR Dealing
PDMR Dealing.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n Allergy Therapeutics plc\n \n \n \n (\"Allergy Therapeutics\" or the \"Company\")\n \n \n PDMR Dealing\n \n \n Issue of 33,333,332 Warrants\n \n \n 3 March 2023 -\n Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces that, further to the Company's announcement on 29 September 2022 regarding the subscription and debt financing, on 28 February 2023 it issued 33,333,332 warrants to subscribe for new Ordinary Shares (\"Warrants\"). \n \n \n As previously announced,\n in conjunction with the issue of Loan Notes, the Company agreed to issue 33,333,332 Warrants to Southern Fox and ZQ Capital, to subscribe for new Ordinary Shares at a Warrant Exercise price of 30 pence per Warrant. The Warrants are exercisable for a period of five years from the Purchase Date of the Loan Notes.\n \n \n Following the issue of Warrants Southern Fox and ZQ Capital will hold the following Warrants over Ordinary Shares in the Company:\n \n \n ·\n Southern Fox: 16,666,666 Warrants; and\n \n \n ·\n ZQ Capital: 16,666,666 Warrants.\n \n \n \n \n \n \n Capitalised terms used and not defined in this announcement have the meanings given to them in the announcement from 29 September 2022.\n \n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n Allergy Therapeutics\n \n \n \n +44 (0)1903 845 820\n \n \n Manuel Llobet, Chief Executive Officer\n \n \n Martin Hopcroft, Interim Chief Financial Officer\n \n \n \n \n \n \n Panmure Gordon (Nominated Adviser and Broker)\n \n \n \n +44 (0)20 7886 2500\n \n \n Freddy Crossley, Emma Earl, Corporate Finance\n \n \n Rupert Dearden, Corporate Broking\n \n \n \n \n \n \n Consilium Strategic Communications\n \n \n \n +44 (0)20 3709 5700\n \n \n Mary-Jane Elliott / David Daley / Davide Salvi\n \n \n \n \n [email protected]\n \n \n \n \n \n About Allergy Therapeutics\n \n \n \n Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major Europea...